NatureCell Co.Ltd
NatureCell Co.,Ltd. manufactures and sells canned and health functional food products, beverages, stem cell, and cosmetics in South Korea and internationally. The company's products comprise fruit drinks, aloe vera drinks, coffee, energy drinks, and Korean sauces, as well as offers domestic products and ETC products under the SAMMI and OEM brands. It also provides services for the preservation of… Read more
NatureCell Co.Ltd (007390) - Net Assets
Latest net assets as of September 2025: ₩62.72 Billion KRW
Based on the latest financial reports, NatureCell Co.Ltd (007390) has net assets worth ₩62.72 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩71.32 Billion) and total liabilities (₩8.60 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩62.72 Billion |
| % of Total Assets | 87.94% |
| Annual Growth Rate | 37.24% |
| 5-Year Change | 3.1% |
| 10-Year Change | 103.95% |
| Growth Volatility | 56.6 |
NatureCell Co.Ltd - Net Assets Trend (2009–2024)
This chart illustrates how NatureCell Co.Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for NatureCell Co.Ltd (2009–2024)
The table below shows the annual net assets of NatureCell Co.Ltd from 2009 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩64.62 Billion | +5.22% |
| 2023-12-31 | ₩61.42 Billion | +7.45% |
| 2022-12-31 | ₩57.16 Billion | -6.06% |
| 2021-12-31 | ₩60.85 Billion | -2.93% |
| 2020-12-31 | ₩62.68 Billion | -23.45% |
| 2019-12-31 | ₩81.89 Billion | +89.87% |
| 2018-12-31 | ₩43.13 Billion | +9.24% |
| 2017-12-31 | ₩39.48 Billion | +16.06% |
| 2016-12-31 | ₩34.02 Billion | +7.36% |
| 2015-12-31 | ₩31.69 Billion | +130.48% |
| 2014-12-31 | ₩13.75 Billion | +82902.36% |
| 2010-12-31 | ₩-16.60 Million | -102.97% |
| 2009-12-31 | ₩559.65 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to NatureCell Co.Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7213670517000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩32.18 Billion | 49.79% |
| Other Components | ₩104.58 Billion | 161.83% |
| Total Equity | ₩64.62 Billion | 100.00% |
NatureCell Co.Ltd Competitors by Market Cap
The table below lists competitors of NatureCell Co.Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Tethys Petroleum Limited
PINK:TETHF
|
$38.43 Million |
|
Unique Engineering and Construction Public Company Limited
BK:UNIQ
|
$38.43 Million |
|
Advanced Analog Technology
TWO:3438
|
$38.43 Million |
|
Mitre Realty Empreendimentos e Participações S.A
SA:MTRE3
|
$38.43 Million |
|
Moberg Pharma AB (publ)
ST:MOB
|
$38.42 Million |
|
Mobix Labs Inc
NASDAQ:MOBX
|
$38.41 Million |
|
Navitas Petroleum Limited Partnership
TA:NVPT
|
$38.41 Million |
|
GetNinjas S.A
SA:NINJ3
|
$38.41 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in NatureCell Co.Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 61,419,188,330 to 64,624,400,670, a change of 3,205,212,340 (5.2%).
- Net income of 1,226,158,110 contributed positively to equity growth.
- Share repurchases of 1,225,045,000 reduced equity.
- New share issuances of 1,225,045,000 increased equity.
- Other factors increased equity by 1,979,054,230.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩1.23 Billion | +1.9% |
| Share Repurchases | ₩1.23 Billion | -1.9% |
| Share Issuances | ₩1.23 Billion | +1.9% |
| Other Changes | ₩1.98 Billion | +3.06% |
| Total Change | ₩- | 5.22% |
Book Value vs Market Value Analysis
This analysis compares NatureCell Co.Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 18.36x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 29.47x to 18.36x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩625.68 | ₩18440.00 | x |
| 2017-12-31 | ₩698.36 | ₩18440.00 | x |
| 2018-12-31 | ₩759.65 | ₩18440.00 | x |
| 2019-12-31 | ₩1338.26 | ₩18440.00 | x |
| 2020-12-31 | ₩1024.38 | ₩18440.00 | x |
| 2021-12-31 | ₩971.55 | ₩18440.00 | x |
| 2022-12-31 | ₩912.53 | ₩18440.00 | x |
| 2023-12-31 | ₩957.32 | ₩18440.00 | x |
| 2024-12-31 | ₩1004.15 | ₩18440.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently NatureCell Co.Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 1.90%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 3.79%
- • Asset Turnover: 0.45x
- • Equity Multiplier: 1.11x
- Recent ROE (1.90%) is above the historical average (-9.69%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 13.78% | 7.47% | 1.03x | 1.78x | ₩520.28 Million |
| 2015 | -4.21% | -4.37% | 0.66x | 1.45x | ₩-4.50 Billion |
| 2016 | -9.48% | -12.03% | 0.51x | 1.55x | ₩-6.63 Billion |
| 2017 | -1.17% | -1.69% | 0.53x | 1.30x | ₩-4.41 Billion |
| 2018 | 5.18% | 8.37% | 0.51x | 1.23x | ₩-2.08 Billion |
| 2019 | 1.10% | 3.91% | 0.25x | 1.14x | ₩-7.29 Billion |
| 2020 | -30.10% | -112.86% | 0.19x | 1.37x | ₩-25.14 Billion |
| 2021 | -52.64% | -144.26% | 0.32x | 1.14x | ₩-38.12 Billion |
| 2022 | -11.92% | -32.06% | 0.23x | 1.64x | ₩-12.53 Billion |
| 2023 | -19.02% | -60.36% | 0.28x | 1.11x | ₩-17.82 Billion |
| 2024 | 1.90% | 3.79% | 0.45x | 1.11x | ₩-5.24 Billion |
Industry Comparison
This section compares NatureCell Co.Ltd's net assets metrics with peer companies in the Pharmaceuticals industry.
Industry Context
- Industry: Pharmaceuticals
- Average net assets among peers: $108,589,281,497
- Average return on equity (ROE) among peers: -0.26%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| NatureCell Co.Ltd (007390) | ₩62.72 Billion | 13.78% | 0.14x | $38.43 Million |
| Sam Chun Dang Pharm. Co. Ltd (000250) | $186.63 Billion | -0.52% | 0.70x | $3.69 Billion |
| DongKoo Bio&Pharma Co. Ltd (006620) | $85.65 Billion | 17.63% | 0.55x | $57.67 Million |
| Sam-A Pharm. Co. Ltd (009300) | $200.47 Billion | 10.66% | 0.15x | $21.19 Million |
| Kyung Dong Pharmaceutical Co. Ltd (011040) | $262.19 Billion | 4.75% | 0.11x | $50.06 Million |
| WooGene B&G Co. Ltd (018620) | $23.04 Billion | -18.19% | 1.63x | $10.47 Million |
| Oscotec Inc (039200) | $26.33 Billion | -13.85% | 0.55x | $947.54 Million |
| EstechPharma Co. Ltd (041910) | $67.96 Billion | 5.45% | 0.54x | $51.23 Million |
| Komipharm International Co. Ltd (041960) | $93.39 Billion | -15.32% | 0.50x | $247.47 Million |
| Eagle Veterinary Technology Co.Ltd (044960) | $31.66 Billion | 7.06% | 0.46x | $20.37 Million |